Virtual histology assessment of cardiac allograft vasculopathy following introduction of everolimus - Results of a multicenter trial

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2700-2709

  Arora, S ^a   Erikstad, I ^a   Ueland, T ^a,h   Sigurdardottir, V ^b   Ekmehag, B ^c   Jansson, K ^d   Eiskjaer H ^d   Botker H E ^e   Mortensen, S A ^f   Saunamaki, K ^f   Gude, E ^a   Ragnarsson, A ^a   Solbu, D ^g   Aukrust, P ^a,h   Gullestad, L ^a,h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f University of Copenhagen   (Denmark)

^g Medical Department   (Norway)

^h UNIVERSITY OF OSLO   (Norway)

Author keywords

Cardiac allograft vasculopathy; everolimus; inflammation; virtual histology

Indexed keywords

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTICLE; CARDIAC ALLOGRAFT VASCULOPATHY; CONTROLLED STUDY; DISEASE COURSE; DRUG CONCENTRATION; FEMALE; GRAFT RECIPIENT; HEART MUSCLE NECROSIS; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SIROLIMUS; VASCULAR DISEASES;

EID: 84867057600     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04234.x     Document Type: Article

References (38)

1. Weis M, von SW,. Cardiac allograft vasculopathy: A review. Circulation 1997; 96: 2069-2077.
2. Taylor DO, Stehlik J, Edwards LB, et al,. Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Heart Transplant Report-2009. J Heart Lung Transplant 2009; 28: 1007-1022.
3. Vassalli G, Gallino A, Weis M, et al,. Alloimmunity and nonimmunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003; 24: 1180-1188.
4. Valantine HA,. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant "atheroma." Transplantation 2003; 76: 891-899.
5. Schmauss D, Weis M,. Cardiac allograft vasculopathy: Recent developments. Circulation 2008; 117: 2131-2141.
6. Moon JI, Kim YS, Kim MS, et al,. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: In vitro study. Transplant Proc 2000; 32: 2026-2027.
7. Xiao F, Chong A, Shen J, et al,. Pharmacologically induced regression of chronic transplant rejection. Transplantation 1995; 60: 1065-1072.
8. Eisen HJ, Tuzcu EM, Dorent R, et al,. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
9. Arora S, Ueland T, Wennerblom B, et al,. Effect of everolimus introduction on cardiac allograft vasculopathy-results of a randomized, multicenter trial. Transplantation 2011; 92: 235-243.
10. Chen WQ, Zhong L, Zhang L, et al,. Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels. Br J Pharmacol 2009; 156: 941-951.
11. Sarno G, Onuma Y, Garcia Garcia HM, et al,. IVUS radiofrequency analysis in the evaluation of the polymeric struts of the bioabsorbable everolimus-eluting device during the bioabsorption process. Catheter Cardiovasc Interv 2010; 75: 914-918.
12. Nasu K, Tsuchikane E, Katoh O, et al,. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology ' with in vitro histopathology. J Am Coll Cardiol 2006; 47: 2405-2412.
13. Nair A, Margolis M, Kuban B, Vince DG,. Automated coronary plaque characterisation with intravascular ultrasound backscatter: Ex vivo validation. EuroIntervention 2007; 3: 113-120.
14. Calvert PA, Obaid DR, O'Sullivan M, et al,. Association between IVUS findings and adverse outcomes in patients with coronary artery disease: The VIVA (VH-IVUS in Vulnerable Atherosclerosis) Study. JACC Cardiovasc Imaging 2011; 4: 894-901.
15. Marso SP, Frutkin AD, Mehta SK, et al,. Intravascular ultrasound measures of coronary atherosclerosis are associated with the Framingham risk score: An analysis from a global IVUS registry. EuroIntervention 2009; 5: 212-218.
16. Gullestad L, Iversen M, Mortensen SA, et al,. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: A multicenter, randomized trial. Transplantation 2010; 89: 864-872.
17. Mintz GS, Nissen SE, Anderson WD, et al,. American college of cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2001; 37: 1478-1492.
18. Bollerslev J, Ueland T, Jorgensen AP, et al,. Positive effects of a physiological dose of GH on markers of atherogenesis: A placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 2006; 154: 537-543.
19. Arora S, Gullestad L, Wergeland R, et al,. Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation. Transplantation 2007; 83: 1308-1315.
20. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG,. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 2200-2206.
21. Raichlin E, Bae JH, Kushwaha SS, et al,. Inflammatory burden of cardiac allograft coronary atherosclerotic plaque is associated with early recurrent cellular rejection and predicts a higher risk of vasculopathy progression. J Am Coll Cardiol 2009; 53: 1279-1286.
22. Raichlin E, Kushwaha SS,. Proliferation signal inhibitors and cardiac allograft vasculopathy. Curr Opin Organ Transplant 2008; 13: 543-550.
23. Eisen H,. Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006; 21 (Suppl 3): iii9-iii13.
24. Eisen HJ, Tuzcu EM, Dorent R, et al,. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
25. Mehra MR, Uber PA,. TOR inhibitors and cardiac allograft vasculopathy: Is inhibition of intimal thickening an adequate surrogate of benefit? J Heart Lung Transplant 2003; 22: 501-504.
26. Delgado JF, Manito N, Segovia J, et al,. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev 2009; 23: 69-79.
27. Johnson DE, Gao SZ, Schroeder JS, DeCampli WM, Billingham ME,. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 1989; 8: 349-359.
28. Valantine HA,. Cardiac allograft vasculopathy: Central role of endothelial injury leading to transplant "atheroma." Transplantation 2003; 76: 891-899.
29. Day JD, Rayburn BK, Gaudin PB, et al,. Cardiac allograft vasculopathy: The central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14: S142-S149.
30. Arora S, Gunther A, Wennerblom B, et al,. Systemic markers of inflammation are associated with cardiac allograft vasculopathy and an increased intimal inflammatory component. Am J Transplant 2010; 10: 1428-1436.
31. Hernandez JM, de Prada JA, Burgos V, et al,. Virtual histology intravascular ultrasound assessment of cardiac allograft vasculopathy from 1 to 20 years after heart transplantation. J Heart Lung Transplant 2009; 28: 156-162.
32. Klauss V, Ackermann K, Spes CH, et al,. Coronary plaque morphologic characteristics early and late after heart transplantation: In vivo analysis with intravascular ultrasonography. Am Heart J 1997; 133: 29-35.
33. Galkina E, Ley K,. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2292-2301.
34. Corti R, Hutter R, Badimon JJ, Fuster V,. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. J Thromb Thrombolysis 2004; 17: 35-44.
35. Vischer UM,. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186-1193.
36. Martinez-Dolz L, Almenar L, Reganon E, et al,. Follow-up study on the utility of von Willebrand factor levels in the diagnosis of cardiac allograft vasculopathy. J Heart Lung Transplant 2008; 27: 760-766.
37. Lehle K, Schreml S, Kunz-Schughart LA, et al,. mTOR inhibitors and calcineurin inhibitors do not affect adhesion molecule expression of human macro- and microvascular endothelial cells. J Vasc Res 2008; 45: 333-342.
38. Manito N, Delgado JF, Crespo-Leiro MG, et al,. Clinical recommendations for the use of everolimus in heart transplantation. Transplant Rev 2010; 24: 129-142.